Nitazoxanide Plus Ribavirin and Peginterferon for Therapy of Treatment Naive HCV Genotype 1 and HIV Coinfected Subjects

Inclusion Criteria: * HIV-1 infection * Documentation of hepatitis C virus (HCV) genotype 1 infection prior to entry * Chronic HCV infection for at least 180 days * CD4+ cell count greater than 200 cells/mm3 obtained within 90 days prior to study entry * Detectable HCV viral load obtained within 90 days prior to study entry * Any change in antiretroviral (ARV) regimen, including initiation of antiretroviral therapy (ART), a switch in ART regimen, or a discontinuation of ART, had to have occurred more than 60 days prior to study entry. Breaks in therapy for a maximum of 14 days total during the 60-day period were allowed. Participants not on ART should have had no plans to initiate therapy during the first 24 weeks after study entry. Participants who did start ART did not have to discontinue study treatment. Participants on ART should have planned to remain on the same therapy for at least 12 weeks after study entry. Changes in formulation or dosage were permitted. * Certain laboratory values obtained within 42 days prior to study entry * Agreement to use contraception, if participating in sexual activity that could lead to pregnancy, for the duration of study and for 6 months afterward * Aspartate aminotransferase (AST), alanine aminotransferase (ALT), and alkaline phosphatase less than or equal to five times the upper limit of normal (ULN) * Hemoglobin \>=11 g/dl for men and \>=10 g/dl for women Exclusion Criteria: * Use of the ARV didanosine (ddI) * Receipt of any interf…